Promoted Content

Promoted Content

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Targovax

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

NORWAY Norway

Post An Enquiry

Virtual Innovation Day

Participation Not Confirmed

Update your events

Targovax Grants IOVaxis 3 Months Extension to the Exclusive License Option for TG Mutant RAS Vaccines in Greater China and Singapore

Contact the Supplier

Lead Product(s): TG01

Therapeutic Area: Oncology Product Name: TG01

Highest Development Status: IND Enabling Product Type: Vaccine

Partner/Sponsor/Collaborator: IOVaxis Therapeutics

Deal Size: $3.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 06, 2021

Details:

Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore.